Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Controlled Trial Evaluating Avacopan in C3 Glomerulopathy
- Conditions
- C3 Glomerulopathy (C3G)
- Interventions
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 57
- Registration Number
- NCT03301467
- Locations
- 🇬🇧
Clinical Site, Newcastle Upon Tyne, United Kingdom
🇺🇸University of Utah, Salt Lake City, Utah, United States
🇺🇸Clinical Trial Site, East Providence, Rhode Island, United States
Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 85
- Registration Number
- NCT03301857
- Locations
- 🇺🇸
Sarcoma Oncology Research Center LLC, Santa Monica, California, United States
🇺🇸Mount Sinai Beth Israel Downtown, New York, New York, United States
🇺🇸University of Minnesota Medical Center Fairview, Minneapolis, Minnesota, United States
Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)
- Conditions
- Secondary HyperparathyroidismChronic Kidney Disease
- Interventions
- First Posted Date
- 2017-10-03
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 637
- Registration Number
- NCT03299244
- Locations
- 🇨🇳
Research Site, Taoyuan, Taiwan
Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study
- Conditions
- Thyroid Eye DiseaseGraves' Orbitopathy
- Interventions
- Biological: TeprotumumabOther: Placebo
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 83
- Registration Number
- NCT03298867
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Bascom Palmer Eye Institute, Miami, Florida, United States
🇺🇸Casey Eye Institute at Oregon Health and Science University, Portland, Oregon, United States
Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2020-09-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 10
- Registration Number
- NCT03298412
- Locations
- 🇨🇭
Research Site, Zurich, Switzerland
Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma
- First Posted Date
- 2017-09-28
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 30
- Registration Number
- NCT03296696
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇳🇱Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands
🇩🇪Universitaetsklinikum Wuerzburg, Würzburg, Germany
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2017-09-19
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 174
- Registration Number
- NCT03287908
- Locations
- 🇨🇦
University Health Network-Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸Winship Cancer Institute Emory U, Atlanta, Georgia, United States
🇺🇸University of Chicago Medical Center - Multiple Myeloma Research Consortium, Chicago, Illinois, United States
Post-Marketing Surveillance Study of OTEZLA
- Conditions
- Psoriasis
- First Posted Date
- 2017-09-15
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1086
- Registration Number
- NCT03284879
- Locations
- 🇯🇵
Tugi dermatology clinic, Kitakyushu, Fukuoka, Japan
A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416
- Conditions
- Secondary Hyperparathyroidism
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 33
- Registration Number
- NCT03283098
- Locations
- 🇨🇳
Research Site, Shanghai, Shanghai, China
Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients
- Conditions
- Heart FailureHealthy Volunteer
- Interventions
- Drug: Placebo PODrug: AMG 986 IVDrug: Placebo IVDrug: AMG 986 PO
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2022-08-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 182
- Registration Number
- NCT03276728
- Locations
- 🇸🇬
Research Site, Singapore, Singapore